F Alaei Shahmiri1, M J Soares, Y Zhao, J Sherriff. 1. School of Public Health, Curtin University, Kent Street, Bentley, Perth, WA, 6102, Australia, fariba.alaeishahmiri@postgrad.curtin.edu.au.
Abstract
PURPOSE: To assess the effect of high-dose oral thiamine supplements on glucose tolerance in patients with impaired glucose metabolism. METHODS:Twelve hyperglycemic subjects (10 cases of impaired glucose tolerance and 2 new cases of type 2 diabetes) completed this randomized, double-blind trial, where all participants received both placebo and thiamine capsules (3 × 100 mg/day) for 6 weeks in a cross-over manner. The main endpoint was changes in 2-h plasma glucose. Fasting plasma glucose and insulin, 2-h plasma insulin, the hemostatic model assessment of insulin resistance (HOMA-IR), renal function measurement and thiamin status were also evaluated at the commencement and completion of each treatment period. RESULTS:Thiamine supplementation resulted in significant decrease in 2-h plasma glucose relative to baseline (8.78 ± 2.20 vs. 9.89 ± 2.50 mmol/l, p = 0.004), with no significant change in the placebo arm. Fasting plasma glucose and insulin, and HOMA-IR increased significantly from baseline after 6 weeks in the placebo arm (p = 0.003, p = 0.04 and p = 0.02, respectively). These variables did not change with thiamine supplementation. There were no significant changes in 2-h plasma insulin or renal function marker, within or between arms. CONCLUSION/ INTERPRETATION: Supplementation with high-dose thiamine may prevent deterioration in fasting glucose and insulin, and improve glucose tolerance in patients with hyperglycemia. High-dose thiamine supplementation may prevent or slow the progression of hyperglycemia toward diabetes mellitus in individuals with impaired glucose regulation.
RCT Entities:
PURPOSE: To assess the effect of high-dose oral thiamine supplements on glucose tolerance in patients with impaired glucose metabolism. METHODS: Twelve hyperglycemic subjects (10 cases of impaired glucose tolerance and 2 new cases of type 2 diabetes) completed this randomized, double-blind trial, where all participants received both placebo and thiamine capsules (3 × 100 mg/day) for 6 weeks in a cross-over manner. The main endpoint was changes in 2-h plasma glucose. Fasting plasma glucose and insulin, 2-h plasma insulin, the hemostatic model assessment of insulin resistance (HOMA-IR), renal function measurement and thiamin status were also evaluated at the commencement and completion of each treatment period. RESULTS:Thiamine supplementation resulted in significant decrease in 2-h plasma glucose relative to baseline (8.78 ± 2.20 vs. 9.89 ± 2.50 mmol/l, p = 0.004), with no significant change in the placebo arm. Fasting plasma glucose and insulin, and HOMA-IR increased significantly from baseline after 6 weeks in the placebo arm (p = 0.003, p = 0.04 and p = 0.02, respectively). These variables did not change with thiamine supplementation. There were no significant changes in 2-h plasma insulin or renal function marker, within or between arms. CONCLUSION/ INTERPRETATION: Supplementation with high-dose thiamine may prevent deterioration in fasting glucose and insulin, and improve glucose tolerance in patients with hyperglycemia. High-dose thiamine supplementation may prevent or slow the progression of hyperglycemia toward diabetes mellitus in individuals with impaired glucose regulation.
Authors: Manuel González-Ortiz; Esperanza Martínez-Abundis; José A Robles-Cervantes; Viridiana Ramírez-Ramírez; Maria G Ramos-Zavala Journal: Eur J Nutr Date: 2010-07-21 Impact factor: 5.614
Authors: Kimihiko Oishi; Susanna Hofmann; George A Diaz; Tartania Brown; Deepa Manwani; Lily Ng; Randy Young; Helen Vlassara; Yiannis A Ioannou; Douglas Forrest; Bruce D Gelb Journal: Hum Mol Genet Date: 2002-11-01 Impact factor: 6.150
Authors: Pankaja Sharma; Nicola Gillies; Shikha Pundir; Chantal A Pileggi; James F Markworth; Eric B Thorstensen; David Cameron-Smith; Amber M Milan Journal: Nutrients Date: 2019-11-28 Impact factor: 5.717